A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy. - GETAID 2014-3 SPARE

GETAID0 个研究点目标入组 300 人开始时间: 2015年6月22日最近更新: 2015年8月4日

适应症

试验速览

暂无简介。

•Diagnosis of Crohn’s disease.
•Male or female, age > 18 years.
•Currently treated with a combination therapy with infliximab and anti-metabolites for luminal Crohn’s disease.
•Combined therapy with scheduled infliximab and anti-metabolites for at least 12 months.
•Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 6 months.
•Antimetabolites administered at a stable dosage for the last 6 months: at least 1 mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated dosage if intolerance to standard dose; at least 15 mg/week subcutaneously for methotrexate.
•Patients in steroid free clinical remission for at least 6 months according to retrospective assessment of the patients’ files.
•CDAI < 150 at baseline.
•A contraceptive during the whole study
•Patients able to understand the information provided to them and to give written informed consent for the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

•Patients who have presented a severe acute or delayed reaction to infliximab.
•Perianal fistulae as the main indication for infliximab treatment
•Active perianal/abdominal fistulae at time of inclusion, defined by active drainage
•Patients with ostomy or ileoanal pouch
•Pregnancy or planned pregnancy during the study
•Inability to follow study procedures as judged by the investigator
•Non-compliant subjects.
•Participation in another therapeutic study

发起方